FOLFIRI + OSE2101
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pancreatic Ductal Adenocarcinoma
Conditions
Pancreatic Ductal Adenocarcinoma, Locally Advanced Cancer, Metastatic Cancer
Trial Timeline
Apr 10, 2021 → Dec 1, 2025
NCT ID
NCT03806309About FOLFIRI + OSE2101
FOLFIRI + OSE2101 is a phase 2 stage product being developed by OSE Immunotherapeutics for Pancreatic Ductal Adenocarcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT03806309. Target conditions include Pancreatic Ductal Adenocarcinoma, Locally Advanced Cancer, Metastatic Cancer.
What happened to similar drugs?
9 of 20 similar drugs in Pancreatic Ductal Adenocarcinoma were approved
Approved (9) Terminated (4) Active (11)
Hype Score Breakdown
Clinical
12
Activity
12
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03806309 | Phase 2 | Active |
Competing Products
20 competing products in Pancreatic Ductal Adenocarcinoma